Find out what drove John McKearn, Ph.D. & CEO at Wugen, out of the lab at Pfizer and on to his quest to develop off-the-shelf cell therapies for T-Cell leukemias and lymphomas, Acute Myeloid Leukemia, and Multiple Myeloma.

A patient in Vienna, Austria was admitted to a local hospital. The 45 year old woman had a 7 day history of cough, weakness, myalgia, fever, and dyspnoea. She also had a 4 day history of nausea and diarrhea. The next day after admittance, her condition worsened, and the patient was put on a ventilator. […]

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Jonathan Javitt, CEO of NeuroRx. Dr Javitt discusses how NeuroRx is working in collaboration with Relief Therapeutics on Aviptadil, a synthetic version of vasoactive intestinal peptide, and a potential treatment of COVID-19 related respiratory […]